Healthy Returns: Weight loss, diabetes drug ad spending tops $1 billion
Publishing timestamp: 2024-04-03 13:33:00
Summary
Drugmakers spent over $1 billion on ads for weight loss and diabetes treatments in 2023, with Novo Nordisk's Ozempic and Wegovy leading the way. Ad spending for these drugs is expected to remain strong or increase in 2024. Prenosis, a health tech startup, received FDA approval for its AI-powered diagnostic tool for sepsis.
Sentiment: NEUTRAL
Tickers: AZN, NVO, LLY, NOVO.B-DK, AZN-GB,
Keywords: astrazeneca plc, eli lilly and co, novo nordisk a/s, health care industry, united states, business news, biotech and pharmaceuticals,
Source: https://www.cnbc.com/2024/04/03/weight-loss-diabetes-drug-ad-spending-tops-1-billion.html